Worldwide Innovative Networking Consortium

While the company reported an increase in revenues from biopharma partners, this gain was more than offset by lower consumable sales.

Illumina is the latest to join the consortium, which is focused on personalizing cancer care.

The algorithm may be able to rationally determine the three-drug strategy with the best chance of overcoming resistance and improving survival in advanced lung cancer patients.

Launched by the Institute Gustav Roussy in France and the University of Texas MD Anderson Cancer Center, the Worldwide Innovative Networking Consortium aims to help drugmakers change the way they develop drugs by focusing on treating diseases with common molecular features, rather than treating disease at an organ site.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.